17 alpha-hydroxylase deficiency epidemiology and demographics

	Congenital adrenal hyperplasia main page
	17 alpha-hydroxylase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating 17 alpha-hydroxylase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
17 alpha-hydroxylase deficiency epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on 17 alpha-hydroxylase deficiency epidemiology and demographics
CDC on 17 alpha-hydroxylase deficiency epidemiology and demographics
17 alpha-hydroxylase deficiency epidemiology and demographics in the news
Blogs on 17 alpha-hydroxylase deficiency epidemiology and demographics
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Overview

17 alpha-hydroxylase deficiency is a rare disease and from 2010, only 130 individuals with severe, confirmed disease had been documented. Worldwide incidence of 17 alpha-hydroxylase deficiency is low, especially compared with other forms of CAH. New cases of 17-hydroxylase deficiency continue to be reported.

Epidemiology and Demographics

Prevalence

17 alpha-hydroxylase deficiency is a rare disease and from 2010, only 130 individuals with severe, confirmed disease had been documented.^[1]

Incidence

Worldwide incidence of 17 alpha-hydroxylase deficiency is low, especially compared with other forms of CAH. New cases of 17-hydroxylase deficiency continue to be reported.^[2]

Age

Patients of all age groups may develop 17 alpha-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood.

Gender

17 alpha-hydroxylase deficiency affects male and female equally.

References

↑ Aydin Z, Ozturk S, Gursu M, Uzun S, Karadag S, Kazancioglu R (2010). "Male pseudohermaphroditism as a cause of secondary hypertension: a case report". Endocrine. 38 (1): 100–3. doi:10.1007/s12020-010-9357-x. PMID 20960109.
↑ Kim YM, Kang M, Choi JH, Lee BH, Kim GH, Ohn JH, Kim SY, Park MS, Yoo HW (2014). "A review of the literature on common CYP17A1 mutations in adults with 17-hydroxylase/17,20-lyase deficiency, a case series of such mutations among Koreans and functional characteristics of a novel mutation". Metab. Clin. Exp. 63 (1): 42–9. doi:10.1016/j.metabol.2013.08.015. PMID 24140098.

Template:WikiDoc Sources

[pmid20960109-1] Aydin Z, Ozturk S, Gursu M, Uzun S, Karadag S, Kazancioglu R (2010). "Male pseudohermaphroditism as a cause of secondary hypertension: a case report". Endocrine. 38 (1): 100–3. doi:10.1007/s12020-010-9357-x. PMID 20960109.

[pmid24140098-2] Kim YM, Kang M, Choi JH, Lee BH, Kim GH, Ohn JH, Kim SY, Park MS, Yoo HW (2014). "A review of the literature on common CYP17A1 mutations in adults with 17-hydroxylase/17,20-lyase deficiency, a case series of such mutations among Koreans and functional characteristics of a novel mutation". Metab. Clin. Exp. 63 (1): 42–9. doi:10.1016/j.metabol.2013.08.015. PMID 24140098.

[1]

[2]